You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

LANOXICAPS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lanoxicaps patents expire, and what generic alternatives are available?

Lanoxicaps is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in LANOXICAPS is digoxin. There are ten drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the digoxin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lanoxicaps

A generic version of LANOXICAPS was approved as digoxin by RISING on December 23rd, 1999.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LANOXICAPS?
  • What are the global sales for LANOXICAPS?
  • What is Average Wholesale Price for LANOXICAPS?
Summary for LANOXICAPS
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 87
Clinical Trials: 1
DailyMed Link:LANOXICAPS at DailyMed
Drug patent expirations by year for LANOXICAPS
Recent Clinical Trials for LANOXICAPS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mirati Therapeutics Inc.Phase 1

See all LANOXICAPS clinical trials

US Patents and Regulatory Information for LANOXICAPS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-002 Jul 26, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-001 Jul 26, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-003 Jul 26, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-004 Sep 24, 1984 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LANOXICAPS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-002 Jul 26, 1982 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-001 Jul 26, 1982 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-004 Sep 24, 1984 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc LANOXICAPS digoxin CAPSULE;ORAL 018118-003 Jul 26, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LANOXICAPS

See the table below for patents covering LANOXICAPS around the world.

Country Patent Number Title Estimated Expiration
Spain 434971 ⤷  Sign Up
Belgium 825842 ⤷  Sign Up
Germany 2507635 ⤷  Sign Up
Austria A133175 ⤷  Sign Up
Italy 1233251 PRERARATO FARMACEUTICO A BASE DI DIGOSSINA PER INGESTIONE ORALE (Digoxin solns in capsule form) ⤷  Sign Up
Luxembourg 71894 ⤷  Sign Up
Australia 501549 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.